Alkeon Capital Management
CERE

Alkeon Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Alkeon Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-699,695
Closed -$22.2M – 130
2023
Q2 		$22.2M Sell
699,695
-36,826
-5% -$1.13M 0.13% 95
2023
Q1 		$18M Sell
736,521
-327,880
-31% -$9.62M 0.12% 102
2022
Q4 		$33.6M Sell
1,064,401
-104,195
-9% -$2.94M 0.25% 94
2022
Q3 		$33M Sell
1,168,596
-42,383
-3% -$1.26M 0.23% 108
2022
Q2 		$32M Sell
1,210,979
-486,397
-29% -$13.8M 0.19% 108
2022
Q1 		$59.4M Sell
1,697,376
-211,659
-11% -$6.18M 0.27% 110
2021
Q4 		$61.9M Sell
1,909,035
-1,217,400
-39% -$43M 0.21% 101
2021
Q3 		$92.2M Buy
3,126,435
+480,000
+18% +$13.5M 0.31% 103
2021
Q2 		$67.8M Buy
2,646,435
+896,435
+51% +$12.8M 0.24% 111
2021
Q1 		$24M Hold
1,750,000
– – 0.09% 135
2020
Q4 		$29M Buy
+1,750,000
New +$22.7M 0.11% 130

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return